Heat Biologics Appoints Senior Vice President of Product Development and Portfolio Strategy

Heat Biologics Inc., a clinical-stage biopharmaceutical company focused on developing therapies to modulate the immune system, has appointed Paul Tebbey, Ph.D. as senior vice president of product development and portfolio strategy.

Tebbey is a pharmaceutical development strategy leader with over 25 years of healthcare and management experience in the biotechnology and pharmaceutical industries at companies such as Abbvie, Baxter, Centocor / Johnson & Johnson and Wyeth / Pfizer.

Tebbey’s research, development and commercial launch experiences include new monoclonal antibodies (STELARA first-in-IL-12/23 class, REMICADE & HUMIRA anti-TNF mAbs), complex vaccines (new conjugate vaccine PREVNAR, virus influenza and respiratory syncytial), biosimilars and targeted small molecule oncolytic molecules (VENCLEXTA). Tebbey earned a doctorate. in Microbiology and Immunology from East Carolina University School of Medicine, where his research focused on T cell signaling, immunosuppression and transformation and completed his postdoctoral studies at Vanderbilt University with a focus on the regulation of gene expression. Tebbey’s publications include over 40 peer-reviewed articles that cover immunology, immune-mediated and infectious diseases, clinical trial design as well as pharmaceutical strategy planning and brand success.

Jeff Wolf, Chief Executive Officer of Heat, commented, “Paul’s track record and track record will help advance our current and planned clinical programs, as well as our extensive ongoing R&D and emerging biosafety initiatives. “

Tebbey said, “I am delighted to join Heat Biologics at this exciting time. Heat has developed a robust clinical platform covering both oncology and infectious diseases. On the R&D front, I look forward to helping advance many value-added clinical programs, as well as Skunkworx, which uses integrated computational and bioinformatics analysis with the goal of accelerating speed and reducing associated costs. drug development.

Source link

Don F. Davis

Leave a Reply

Your email address will not be published.